1 Introduction 5

• 1.1 Industry Definition and Research Scope 5
  • 1.1.1 Industry Definition 5
  • 1.1.2 Research Scope 6
• 1.2 Research Methodology 8
  • 1.2.1 Overview of Market Research Methodology 8
  • 1.2.2 Market Assumption 9
  • 1.2.3 Secondary Data 9
  • 1.2.4 Primary Data 9
  • 1.2.5 Data Filtration and Model Design 10
  • 1.2.6 Market Size/Share Estimation 11
  • 1.2.7 Research Limitations 12
• 1.3 Executive Summary 13

2 Market Overview and Dynamics 15

• 2.1 Market Size and Forecast 15
• 2.2 Major Growth Drivers 16
• 2.3 Market Restraints and Challenges 19
• 2.4 Emerging Opportunities and Market Trends 22
• 2.5 Porter’s Fiver Forces Analysis 25

3 Segmentation of North America Market by Product Type 29

• 3.1 Market Overview by Product Type 29
• 3.2 Human Insulin Drugs 31
• 3.3 Human Insulin Delivery Devices 32

4 Segmentation of North America Human Insulin Drugs Market by Drug Product 33

• 4.1 Market Overview by Drug Product 33
• 4.2 Modern Human Insulin 35
  • 4.2.1 Modern Human Insulin by Type 37
  • 4.2.2 Modern Human Insulin by Brand 41
• 4.3 Traditional Human Insulin 48
  • 4.3.1 Traditional Human Insulin by Type 50
  • 4.3.2 Traditional Human Insulin by Brand 53

5 Segmentation of North America Human Insulin Delivery Devices Market by Device Product 56

• 5.1 Market Overview by Product 56
• 5.2 Syringes 58
• 5.3 Pens 59
• 5.4 Pumps 60
• 5.5 Other Devices 62

6 Segmentation of North America Market by Application 63

• 6.1 Market Overview by Application 63
• 6.2 Type 1 Diabetes 65
• 6.3 Type 2 Diabetes 66
• 6.4 Gestational Diabetes and Prediabetes 67

7 Segmentation of North America Market by Distribution Channel 68

• 7.1 Market Overview by Distribution Channel 68
• 7.2 Hospital Pharmacies 70
• 7.3 Retail Pharmacies 71
• 7.4 Online Pharmacies 72

8 North America Market 2019-2026 by Country 73

• 8.1 Overview of North America Market 73
• 8.2 U.S. Market 76
• 8.3 Canadian Market 80

9 Competitive Landscape 82

• 9.1 Overview of Key Vendors 82
• 9.2 New Product Launch, Partnership, Investment, and M&A 86
• 9.3 Company Profiles 88

Astra Zeneca PLC 88

Biocon 90

Eli Lilly 91

Exir 92

Julphar 93

Novo Nordisk AS 94

Pfizer 95

Sanofi Aventis 96

Sedico 97

Wockhardt 98

10 Investing in North America Market: Risk Assessment and Management 99

• 10.1 Risk Evaluation of North America Market 99
• 10.2 Critical Success Factors (CSFs) 102

Related Reports and Products 105

North America human insulin market is expected to reach $23.52 billion by 2025, growing by 7.36% annually over the next years.
Highlighted with 27 tables and 52 figures, this 105-page report “North America Human Insulin Market 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America human insulin market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. In this report 2019 is the base year for market analysis, with estimates and forecast covering 2020-2026. (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify North America human insulin market in every aspect of the classification from perspectives of Product Type, Application, Distribution Channel, and Country.
Based on product type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Human Insulin Drugs
• Human Insulin Delivery Devices
Based on product, the North America Human Insulin Drugs market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Modern Human Insulin (further segmented into Long-acting, Rapid- acting, Premixed by type; further segmented into Lantus, Apidra, Levemir, NovoRapid/ NovoLog, Novomix, Humalog, Others by brand)
• Traditional Human Insulin (further segmented into Short-acting, Intermediate & Rapid-acting, Premixed by type; further segmented into Humulin, Insuman, Novolin/Actrapid/Insulatard by brand)
Based on product, the North America Human Insulin Delivery Devices market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Syringes
• Pens (further segmented into Disposable, Reusable, Pen needles)
• Pumps
• Others
Based on application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes and Prediabetes
Based on distribution channel, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
For each of the aforementioned countries, market analysis and revenue data are available for 2019-2026. The breakdown of major national markets by Product Type, Application, and Distribution Channel over the study years (2019-2026) is included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America human insulin market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players:
Astra Zeneca PLC
Biocon
Eli Lilly
Exir
Julphar
Novo Nordisk AS
Pfizer
Sanofi Aventis
Sedico
Wockhardt
(Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)